Asia-Pacific Human Insulin Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Asia-Pacific Human Insulin Market is segmented by Product Type (Basal or Long Acting Insulin, Bolus or Fast Acting Insulin, Traditional Human Insulin, Biosimilar Insulin, and Combination Insulin) and Geography.

Market Snapshot

Asia
Study Period: 2018 - 2026
Base Year: 2020
CAGR: 0 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Asia-Pacific human insulin market (henceforth, referred to as the market studied) is expected to register a CAGR of 4.31% during the forecast period of 2019-2024, and the market studied is estimated to reach a value of USD 7 billion by 2019. 

  • Diabetes ranks among the fast-growing chronic diseases in the Asia-Pacific region, especially in the countries like China, India, and Japan. China dominates the market studied, due to the growing prevalence of diabetes and obesity, and favorable regulatory scenario in the region.
  • The genetic factor is one of the primary reasons for the rapid spread of the disease. Sedentary lifestyles and obesity are the other factors responsible for the high prevalence of the disease.
  • Although insulin has been used for the treatment of diabetes for over 90 years, more than half of those who need insulin today still cannot afford and access it due to the high cost of the product.

Scope of the Report

The Asia-Pacific Human Insulin Market is segmented by Product Type (Basal or Long Acting Insulin, Bolus or Fast Acting Insulin, Traditional Human Insulin, Biosimilar Insulin, and Combination Insulin) and Geography.

By Product Type
Insulin (Value and Volume 2012-2024)
Basal or Long Acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Abasaglar (Insulin Glargine)
Bolus or Fast Acting Insulins
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
FIASP (Insulin Aspart)
Admelog (Insulin Lispro)
Traditional Human Insulins
Novolin/Actrapid/Insulatard
Humilin
Insuman
Insulin Combinations
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Soliqua/Suliqua (Insulin Glargine and Lixisenatide)
Biosimilar Insulins
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Geography
Asia-Pacific
Australia (Value and Volume 2012-2024)
Basal or Long Acting Insulins
Bolus or Fast Acting Insulins
Traditional Human Insulins
Biosimilar Insulins
Insulin Combinations
By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)
China (Value and Volume 2012-2024)
Basal or Long Acting Insulins
Bolus or Fast Acting Insulins
Traditional Human Insulins
Biosimilar Insulins
Insulin Combinations
By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)
India (Value and Volume 2012-2024)
Basal or Long Acting Insulins
Bolus or Fast Acting Insulins
Traditional Human Insulins
Biosimilar Insulins
Insulin Combinations
By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)
Indonesia (Value and Volume 2012-2024)
Basal or Long Acting Insulins
Bolus or Fast Acting Insulins
Traditional Human Insulins
Biosimilar Insulins
Insulin Combinations
By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)
Japan (Value and Volume 2012-2024)
Basal or Long Acting Insulins
Bolus or Fast Acting Insulins
Traditional Human Insulins
Biosimilar Insulins
Insulin Combinations
By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)
Malaysia (Value and Volume 2012-2024)
Basal or Long Acting Insulins
Bolus or Fast Acting Insulins
Traditional Human Insulins
Biosimilar Insulins
Insulin Combinations
By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)
Philippines (Value and Volume 2012-2024)
Basal or Long Acting Insulins
Bolus or Fast Acting Insulins
Traditional Human Insulins
Biosimilar Insulins
Insulin Combinations
By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)
South Korea (Value and Volume 2012-2024)
Basal or Long Acting Insulins
Bolus or Fast Acting Insulins
Traditional Human Insulins
Biosimilar Insulins
Insulin Combinations
By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)
Thailand (Value and Volume 2012-2024)
Basal or Long Acting Insulins
Bolus or Fast Acting Insulins
Traditional Human Insulins
Biosimilar Insulins
Insulin Combinations
By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)
Vietnam (Value and Volume 2012-2024)
Basal or Long Acting Insulins
Bolus or Fast Acting Insulins
Traditional Human Insulins
Biosimilar Insulins
Insulin Combinations
By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)
Rest of Asia-Pacific (Value and Volume 2012-2024)
Basal or Long Acting Insulins
Bolus or Fast Acting Insulins
Traditional Human Insulins
Biosimilar Insulins
Insulin Combinations
By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)

Report scope can be customized per your requirements. Click here.

Key Market Trends

Surge in Diabetic Population

  • There would be a massive surge in diabetic population in the Asia-Pacific region. The burden of diabetes is increasing, and it is expected to grow at a high rate in the Asia-pacific region. 
  • The Asia-Pacific region dominates the diabetes market, globally, contributing to 60% of the diabetes population. 
  • China and India have the highest diabetes population, especially type-2. China has over 11% of its population suffering from diabetes, and in India, 5% of the population suffers from diabetes. 
  • Poor healthcare infrastructure and utilization and lack of awareness about the disease in other countries of Asia-Pacific have complicated its prevalence. Furthermore, in these areas, most of the cases are uncontrolled or even undiagnosed, until patients get symptoms of complications. Factors, such as lack of awareness about the disease, unbalanced nutrition, and inadequate healthcare infrastructure and utilization, are restraining the insulin market in the region.  
Asia pacific Insulin

China dominates the Asia-Pacific Human Insulin Market

  • China is anticipated to hold the largest market share and is expected to maintain its dominant position during the forecast period, owing to huge patient pools and the ease in the regulatory process for insulin biosimilar drugs in the country.
  • The incidence of type-2 diabetes (T2D) has rapidly increased over recent decade, and T2D has become a leading public health challenge in China. 
  • There is a considerable rise in the biosimilar drugs market in the Asia-Pacific, and China's Gan&Lee Basalin occupies almost 40% of the overall Glargine market. 
China Insulin

Competitive Landscape

  • The Asia-Pacific human insulin market is highly consolidated, with three major manufacturers having a large market share. However, many local companies have brought biosimilar insulin in the market at a much cheaper price.
  • Mergers and acquisitions that happened between the players in the recent past helped the companies to strengthen their market presence.
  • Cipla has partnered with Eli Lilly to market and distribute Lilly’s insulin glargine injection, basaglar, in India.
  • Sandoz partnered with Gan&Lee for the commercialization of insulin developed by Gan&Lee. Sandoz is likely to be fully responsible for commercializing these medicines in the EU, the United States, Switzerland, Japan, South Korea, Canada, Australia, and New Zealand.  

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Drivers

    3. 4.3 Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product Type

      1. 5.1.1 Insulin (Value and Volume 2012-2024)

        1. 5.1.1.1 Basal or Long Acting Insulins

          1. 5.1.1.1.1 Lantus (Insulin Glargine)

          2. 5.1.1.1.2 Levemir (Insulin Detemir)

          3. 5.1.1.1.3 Toujeo (Insulin Glargine)

          4. 5.1.1.1.4 Tresiba (Insulin Degludec)

          5. 5.1.1.1.5 Abasaglar (Insulin Glargine)

        2. 5.1.1.2 Bolus or Fast Acting Insulins

          1. 5.1.1.2.1 NovoRapid/Novolog (Insulin Aspart)

          2. 5.1.1.2.2 Humalog (Insulin Lispro)

          3. 5.1.1.2.3 Apidra (Insulin Glulisine)

          4. 5.1.1.2.4 FIASP (Insulin Aspart)

          5. 5.1.1.2.5 Admelog (Insulin Lispro)

        3. 5.1.1.3 Traditional Human Insulins

          1. 5.1.1.3.1 Novolin/Actrapid/Insulatard

          2. 5.1.1.3.2 Humilin

          3. 5.1.1.3.3 Insuman

        4. 5.1.1.4 Insulin Combinations

          1. 5.1.1.4.1 NovoMix (Biphasic Insulin Aspart)

          2. 5.1.1.4.2 Ryzodeg (Insulin Degludec and Insulin Aspart)

          3. 5.1.1.4.3 Xultophy (Insulin Degludec and Liraglutide)

          4. 5.1.1.4.4 Soliqua/Suliqua (Insulin Glargine and Lixisenatide)

        5. 5.1.1.5 Biosimilar Insulins

          1. 5.1.1.5.1 Insulin Glargine Biosimilars

          2. 5.1.1.5.2 Human Insulin Biosimilars

    2. 5.2 Geography

      1. 5.2.1 Asia-Pacific

        1. 5.2.1.1 Australia (Value and Volume 2012-2024)

          1. 5.2.1.1.1 Basal or Long Acting Insulins

          2. 5.2.1.1.2 Bolus or Fast Acting Insulins

          3. 5.2.1.1.3 Traditional Human Insulins

          4. 5.2.1.1.4 Biosimilar Insulins

          5. 5.2.1.1.5 Insulin Combinations

          6. 5.2.1.1.6 By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)

        2. 5.2.1.2 China (Value and Volume 2012-2024)

          1. 5.2.1.2.1 Basal or Long Acting Insulins

          2. 5.2.1.2.2 Bolus or Fast Acting Insulins

          3. 5.2.1.2.3 Traditional Human Insulins

          4. 5.2.1.2.4 Biosimilar Insulins

          5. 5.2.1.2.5 Insulin Combinations

          6. 5.2.1.2.6 By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)

        3. 5.2.1.3 India (Value and Volume 2012-2024)

          1. 5.2.1.3.1 Basal or Long Acting Insulins

          2. 5.2.1.3.2 Bolus or Fast Acting Insulins

          3. 5.2.1.3.3 Traditional Human Insulins

          4. 5.2.1.3.4 Biosimilar Insulins

          5. 5.2.1.3.5 Insulin Combinations

          6. 5.2.1.3.6 By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)

        4. 5.2.1.4 Indonesia (Value and Volume 2012-2024)

          1. 5.2.1.4.1 Basal or Long Acting Insulins

          2. 5.2.1.4.2 Bolus or Fast Acting Insulins

          3. 5.2.1.4.3 Traditional Human Insulins

          4. 5.2.1.4.4 Biosimilar Insulins

          5. 5.2.1.4.5 Insulin Combinations

          6. 5.2.1.4.6 By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)

        5. 5.2.1.5 Japan (Value and Volume 2012-2024)

          1. 5.2.1.5.1 Basal or Long Acting Insulins

          2. 5.2.1.5.2 Bolus or Fast Acting Insulins

          3. 5.2.1.5.3 Traditional Human Insulins

          4. 5.2.1.5.4 Biosimilar Insulins

          5. 5.2.1.5.5 Insulin Combinations

          6. 5.2.1.5.6 By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)

        6. 5.2.1.6 Malaysia (Value and Volume 2012-2024)

          1. 5.2.1.6.1 Basal or Long Acting Insulins

          2. 5.2.1.6.2 Bolus or Fast Acting Insulins

          3. 5.2.1.6.3 Traditional Human Insulins

          4. 5.2.1.6.4 Biosimilar Insulins

          5. 5.2.1.6.5 Insulin Combinations

          6. 5.2.1.6.6 By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)

        7. 5.2.1.7 Philippines (Value and Volume 2012-2024)

          1. 5.2.1.7.1 Basal or Long Acting Insulins

          2. 5.2.1.7.2 Bolus or Fast Acting Insulins

          3. 5.2.1.7.3 Traditional Human Insulins

          4. 5.2.1.7.4 Biosimilar Insulins

          5. 5.2.1.7.5 Insulin Combinations

          6. 5.2.1.7.6 By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)

        8. 5.2.1.8 South Korea (Value and Volume 2012-2024)

          1. 5.2.1.8.1 Basal or Long Acting Insulins

          2. 5.2.1.8.2 Bolus or Fast Acting Insulins

          3. 5.2.1.8.3 Traditional Human Insulins

          4. 5.2.1.8.4 Biosimilar Insulins

          5. 5.2.1.8.5 Insulin Combinations

          6. 5.2.1.8.6 By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)

        9. 5.2.1.9 Thailand (Value and Volume 2012-2024)

          1. 5.2.1.9.1 Basal or Long Acting Insulins

          2. 5.2.1.9.2 Bolus or Fast Acting Insulins

          3. 5.2.1.9.3 Traditional Human Insulins

          4. 5.2.1.9.4 Biosimilar Insulins

          5. 5.2.1.9.5 Insulin Combinations

          6. 5.2.1.9.6 By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)

        10. 5.2.1.10 Vietnam (Value and Volume 2012-2024)

          1. 5.2.1.10.1 Basal or Long Acting Insulins

          2. 5.2.1.10.2 Bolus or Fast Acting Insulins

          3. 5.2.1.10.3 Traditional Human Insulins

          4. 5.2.1.10.4 Biosimilar Insulins

          5. 5.2.1.10.5 Insulin Combinations

          6. 5.2.1.10.6 By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)

        11. 5.2.1.11 Rest of Asia-Pacific (Value and Volume 2012-2024)

          1. 5.2.1.11.1 Basal or Long Acting Insulins

          2. 5.2.1.11.2 Bolus or Fast Acting Insulins

          3. 5.2.1.11.3 Traditional Human Insulins

          4. 5.2.1.11.4 Biosimilar Insulins

          5. 5.2.1.11.5 Insulin Combinations

          6. 5.2.1.11.6 By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)

  6. 6. MARKET INDICATORS

    1. 6.1 Type-1 Diabetic Population (2012-2024)

    2. 6.2 Type-2 Diabetic Population (2012-2024)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 Company Profiles

      1. 7.1.1 Novo Nordisk

      2. 7.1.2 Eli Lilly

      3. 7.1.3 Sanofi

      4. 7.1.4 Biocon

      5. 7.1.5 Gan & Lee

      6. 7.1.6 Wockhardt

    2. 7.2 Company Share Analysis

      1. 7.2.1 Novo Nordisk

      2. 7.2.2 Eli Lilly

      3. 7.2.3 Sanofi

      4. 7.2.4 Other Companies

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
Market size and volume of individual drugs provided for every country

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Asia-Pacific Human Insulin Market market is studied from 2018 - 2026.

The Asia-Pacific Human Insulin Market is growing at a CAGR of 0% over the next 5 years.

Novo Nordisk, Eli Lilly, Sanofi, Biocon, Gan & Lee are the major companies operating in Asia-Pacific Human Insulin Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!